High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma (Q39470973)

12 September 2017

title

High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma (English)

1 reference

12 September 2017

0 references

1 reference

Chen Lin

1 reference

12 September 2017

Zaizhong Zhang

1 reference

12 September 2017

Yun Xu

1 reference

12 September 2017

Ruohan Wang

1 reference

12 September 2017

Shaoquan Chen

1 reference

12 September 2017

Jian Gao

1 reference

12 September 2017

Daiyong Wang

1 reference

12 September 2017

Qiaojia Huang

1 reference

12 September 2017

Xiaohuang Tu

1 reference

12 September 2017

Lie Wang

1 reference

American Journal of Clinical Pathology

12 September 2017

language of work or name

English

1 reference

inferred from

publication date

1 September 2016

1 reference

American Journal of Clinical Pathology

12 September 2017

published in

1 reference

12 September 2017

volume

146

1 reference

12 September 2017

1 reference

12 September 2017

page(s)

278-288

1 reference

12 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Molecular basis of therapeutic approaches to gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Roles of VEGF-A signalling in development, regeneration, and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJCP%2FAQW110

21 January 2018

Identifiers

DOI

10.1093/AJCP/AQW110

1 reference

12 September 2017

1 reference